Senseonics Announces a Collaboration with the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio
September 13 2021 - 4:05PM
Business Wire
--The University Hospitals Accountable Care Organization places
patients on the Eversense CGM System
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and commercialization
of the first and only long-term, implantable continuous glucose
monitoring (CGM) system for people with diabetes, and Ascensia
Diabetes Care, the makers of the CONTOUR® family of diabetes blood
glucose monitoring devices and commercialization partner for
Senseonics, have announced that the University Hospitals
Accountable Care Organization (UHACO) in Cleveland, Ohio has begun
offering the Eversense® CGM System to its Medicare enrollees
effective early September, 2021. The recent decision to use the
Eversense CGM System in eligible patients with type 1 diabetes or
type 2 diabetes on insulin shows the commitment of UHACO to
facilitate optimal diabetes management for its enrollees.
“We are excited to offer Eversense to our ACO patients with
diabetes. Supplying tools for effective glucose management allows
us to meet the Standards of Care for patients using insulin as
outlined by the American Diabetes Association,” said Betul
Hatipoglu, M.D., Head of Endocrinology and Diabetes at UHACO.
“Eversense offers patients choice amongst continuous glucose
monitoring devices. The Eversense CGM system delivers industry
leading accuracy, an improved patient experience, and an array of
unique features that afford people, especially those in the
Medicare population, the opportunity to achieve improved health
outcomes.”
Established in 2010, the mission of the University Hospitals
Accountable Care Organization (UHACO) is to improve the health and
wellness of employees and their dependents who are enrolled in a UH
employee medical plan. UHACO has expansive care coordination and
disease management programs to promote wellness and prevention, and
improve population health.
The Eversense CGM System consists of a fluorescence-based
sensor, a smart transmitter worn over the sensor to facilitate data
communication, and a mobile app for displaying glucose values,
trends and alerts. In addition to featuring the first long-term and
first implantable CGM sensor, the system is also first to feature a
smart transmitter that provides wearers with discreet on-body
vibratory alerts for high and low glucose and can be removed,
recharged and re-attached to the skin without discarding the sensor
The sensor is inserted subcutaneously in the upper arm by a health
care provider via a brief in-office procedure.
Patients who are interested in getting started on Eversense can
sign up at www.eversensediabetes.com/get-started-today. Physicians,
nurse practitioners or physician assistants interested in offering
the Eversense CGM System for their patients can contact 844-SENSE4U
(844-736-7348).
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels in persons age
18 and older with diabetes for up to 90 days. The system is
indicated for use to replace fingerstick blood glucose (BG)
measurements for diabetes treatment decisions. Fingerstick BG
measurements are still required for calibration twice per day, and
when symptoms do not match CGM information or when taking
medications of the tetracycline class. The sensor insertion and
removal procedures are performed by a health care provider. The
Eversense CGM System is a prescription device; patients should talk
to their health care provider to learn more. For important safety
information, see https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the design, development and commercialization of
transformational glucose monitoring products designed to help
people with diabetes confidently live their lives with ease.
Senseonics' CGM systems, Eversense® and Eversense® XL, include a
small sensor inserted completely under the skin that communicates
with a smart transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Senseonics, including statements about the
growth in use by patients or organizations, and the potential
benefits Eversense offers people with diabetes, and other
statements containing the words “believe,” “expect,” “intend,”
“may,” “projects,” “will,” “planned,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
uncertainties in the development and regulatory approval processes,
uncertainties inherent in the commercial launch and commercial
expansion of the product, uncertainties inherent in the transition
of commercialization responsibilities to Ascensia, uncertainties in
insurer, regulatory and administrative processes and decisions,
uncertainties in the duration and severity of the Covid-19
pandemic, and such other factors as are set forth in the risk
factors detailed in Senseonics’ Annual Report on Form 10-K for the
year ended December 31, 2020, Senseonics’ Quarterly Report on Form
10-Q for the quarter ended June 30, 2021, and Senseonics’ other
filings with the SEC under the heading “Risk Factors.” In addition,
the forward-looking statements included in this press release
represent Senseonics’ views as of the date hereof. Senseonics
anticipates that subsequent events and developments will cause
Senseonics’ views to change. However, while Senseonics may elect to
update these forward-looking statements at some point in the
future, Senseonics specifically disclaims any obligation to do so
except as required by law. These forward-looking statements should
not be relied upon as representing Senseonics’ views as of any date
subsequent to the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210913005805/en/
Senseonics Investor Contact Lynn Lewis or Philip Taylor
Investor Relations 415-937-5406 investors@senseonics.com
Senseonics Media Contact: Mirasol Panlilio
301-556-1631
Senseonics (AMEX:SENS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Jul 2023 to Jul 2024